EverSource Wealth Advisors LLC Acquires 282 Shares of Edwards Lifesciences Co. (NYSE:EW)

EverSource Wealth Advisors LLC raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 27.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,304 shares of the medical research company’s stock after purchasing an additional 282 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. GSA Capital Partners LLP purchased a new stake in Edwards Lifesciences during the third quarter worth about $481,000. Empowered Funds LLC grew its position in shares of Edwards Lifesciences by 10.7% during the 3rd quarter. Empowered Funds LLC now owns 24,032 shares of the medical research company’s stock valued at $1,586,000 after acquiring an additional 2,324 shares during the period. Swiss National Bank increased its stake in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Swiss National Bank now owns 1,788,600 shares of the medical research company’s stock worth $118,030,000 after purchasing an additional 8,300 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $406,000. Finally, W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in Edwards Lifesciences in the third quarter valued at approximately $7,290,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Citigroup boosted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group raised their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Stock Down 0.5 %

Shares of NYSE:EW opened at $70.31 on Wednesday. The firm has a market capitalization of $41.33 billion, a PE ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a fifty day moving average of $71.61 and a 200 day moving average of $70.35.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,303 shares of company stock worth $3,715,776 over the last ninety days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.